Jefferies sets CNY 166.00 target for Mindray stock
Published on 10/14/2026 at 07:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting figures
- On October 13, 2026, Jefferies assigned Mindray a CNY 166.00 target.
- Revenue rose 6.00 percent in the first half of 2026 to CNY 17.75 billion.
- Mindray stock costs CNY 165.65 on October 14, 2026 at 1:27 p.m. CST, up 0.43 percent on Shenzhen.
- The price-to-earnings ratio was 25.47 and market capitalization was CNY 200.8 billion on October 14, 2026.
Jefferies assigned Mindray Bio-Medical a CNY 166.00 price target on October 13, 2026, according to Futu. The target sits CNY 0.35 above the latest Shenzhen quote, making the analyst figure a near-term valuation reference rather than a large forecast gap. Mindray stock stood at CNY 165.65 on October 14, 2026 at 1:27 p.m. CST, up 0.43 percent on Shenzhen from CNY 164.94.
Revenue reached CNY 17.75 billion
Mindray reported revenue of RMB 17.747 billion in the first half of 2026, up 6.00 percent year over year, while net profit attributable to shareholders reached RMB 4.797 billion, down 5.37 percent. Those figures were reported by Futu in its September 30, 2026 report on the company. The split between revenue growth and lower profit keeps margin pressure central to the valuation discussion.
The same report said overseas revenue rose 13.67 percent to RMB 9.471 billion in the first half, while emerging-business revenue increased 19.59 percent to RMB 3.110 billion. Overseas sales therefore grew faster than total revenue, although domestic revenue declined 1.61 percent to RMB 8.276 billion.
Stock remains inside its yearly range
The Shenzhen-listed stock traded between CNY 130.66 and CNY 239.79 over the latest 52-week period. At CNY 165.65, it stood CNY 74.14 below the high and CNY 34.99 above the low, placing the quote closer to the lower half of the range.
Market capitalization was CNY 200.8 billion on October 14, 2026, and the price-to-earnings ratio was 25.47. The latest quote showed 3,308,408 shares traded against an average volume of 9,425,736 shares.
Comparison with peers
Mindray: up 0.43 percent, price-to-earnings ratio 25.47, market capitalization CNY 200.8 billion
Shanghai United Imaging Healthcare (Shanghai Stock Exchange, CNY): up 0.39 percent, price-to-earnings ratio 77.96, market capitalization CNY 87.9 billion
Lepu Medical Technology (Shenzhen Stock Exchange, CNY): up 0.09 percent, price-to-earnings ratio 27.32, market capitalization CNY 21.2 billion
Trading context for medical devices
Mindray operates in healthcare and medical devices, with products spanning patient monitoring, life support, in-vitro diagnostics and medical imaging. Its 2026 first-half results show a company balancing international expansion against weaker domestic demand and lower reported profit.
Market context: Market report Shanghai Composite.
Mindray stock at a glance
- Company: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- ISIN: CNE100003G67
- Ticker: 300760.SZ
- Primary exchange: Shenzhen Stock Exchange
- Price Shenzhen Stock Exchange (as of October 14, 2026, 1:27 p.m. CST): CNY 165.65
- Change versus prior close: plus 0.43 percent
- Prior close Shenzhen Stock Exchange (October 13, 2026): CNY 164.94
- Market capitalization: CNY 200.8 billion (as of October 14, 2026)
- 52-week range: CNY 130.66-CNY 239.79 (as of October 14, 2026)
- Sector / Industry: Healthcare / Medical Devices
More news and analyses on Mindray stock.
